Summit Therapeutics filed a prospectus supplement to its automatic shelf registration statement on Form S-3. This 8-K filing includes the legal opinion of Baker & Hostetler LLP regarding the validity of the common stock issuance described in that supplement. The company operates in the biopharmaceutical industry, focusing on drug development.
